trending Market Intelligence /marketintelligence/en/news-insights/trending/um8pjsjz8d7mkwmz4urm9a2 content esgSubNav
In This List

Orexigen Therapeutics gets delisting notice from Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Orexigen Therapeutics gets delisting notice from Nasdaq

Orexigen Therapeutics Inc. said it received a delisting notice from Nasdaq Stock Market LLC after filing for Chapter 11 bankruptcy protection.

The La Jolla, Calif.-based biopharmaceutical previously received a noncompliance notice after failing to meet Nasdaq's $50 million minimum market value of listed securities rule.

Orexigen was given until March 19 to present its case before the Nasdaq Hearings Panel. However, the company said it is not in the position to do so due to lack of sufficient materials.

The company expects to receive a delisting determination from the Panel, along with the trading suspension of its securities on the Nasdaq Global Select Market.